Leadership

Anthony Rohr, B.S., LATG, CLSSBB

Director of Business Development

Anthony joined the team in 2018. In his 6 years with the organization, he has had several different operational and business development roles. As Director of the business development team, he will provide leadership, oversight, and coordination of the business development and marketing activities.

,

Anthony brought over 20 years of experience in the Preclinical Research industry to the team. He previously held a position with MPI Research, Inc., as Senior Director of Operations. Anthony was also the owner of Knowledgeable and Focused Consulting, where he provided science and business development consultation services to Biotech, CRO, and Pharma.

,

Anthony received his B.S. in Biomedical Sciences from Western Michigan University in Kalamazoo, MI and is a certified lean six sigma black belt.

• 269-492-3872
• arohr@gd3services.com
• 

Christopher Dillon, B.A., LATG, CPIA

Chief Operating Officer

Christopher Joined the team in 2023. As Chief Operating Officer, he is responsible for the overall operation and coordination of all GD³ site senior leadership teams to identify continuous improvement opportunities, execute corporate policies and strategic plans, and monitor quality and performance. Lead, facilitate, and report on strategic discussions and harmonization efforts for all GD³ sites to the CEO and global leadership team. Liaise with the Chief Scientific Officers in the evaluation and implementation of added scientific services or refinements to existing services.

Christopher brought more than 15 years of experience in the leadership and management of contract research organizations. He is well-versed in strategic and tactical planning, process improvement, compliance, animal welfare, and due diligence activities. Christopher previously held key positions at Sir Home and SIR Home Cares as Director of Operations, Sales and Business Development, MPI Research/CRL as Vice President, Chief Compliance Officer & IACUC Chair, and Somnio Global as Senior Director Product Development and Quality.

Christopher received a BA in Biomedical Ethics from Western Michigan University in Kalamazoo, MI.

• 269-207-3281
• cdillon@gd3services.com
• 

Graham Fletcher, Ph.D.

Chief Operating Officer, Disease Modeling Division

Dr. Fletcher joined the team in 2024. As Chief Operating Officer of the Disease Modeling Division of GD³, he provides leadership, oversight, and coordination for developing and managing operational components, including IACUC and GLP compliance activities and internal study scheduling. He works closely with clients and the Business Development team to understand their needs, design projects, and oversee their studies.

Dr. Fletcher is an accomplished preclinical and clinical drug development scientist and pharmacologist who has held senior roles in small molecule and therapeutic antibody programs. He brought to the team over 20 years of experience covering the drug development process from target discovery and validation through Phase I/II clinical trials with particular therapeutic expertise in Oncology and Immuno-oncology (IO). Dr. Fletcher has extensive experience in team and project management, leading multidisciplinary teams to take three oncology drugs from candidate selection through IND development into nine clinical trials. He deeply understands the drug development process and oncology and IO, encompassing biological, translational, and clinical science. He previously held positions with EntreMed Inc. as a Research Scientist III, Campbell Family Institute, within the University Health Network, Toronto and Treadwell Therapeutics as Head of Preclinical Development, and Medicenna Therapeutics as Director of Clinical Science.

Dr. Fletcher received a BSc in Molecular Biology at Edinburgh University in Edinburgh, Scotland. He earned a Ph.D. in Cell Biology from the University of Cambridge in Cambridge, United Kingdom. Dr. Fletcher is an author of over 20 publications and patents.

• 416-939-9590
• gfletcher@gd3services.com
• 

Chiayu (Joyce) Huang, Ph.D.

Chief Scientific Officer, Chemistry

Dr. Huang joined the team in 2010. As the Chief Scientific Officer of Chemistry, she oversees a team of medicinal chemists in the optimization of small molecule therapeutic compounds aimed at immuno-oncology targets, metabolic disorders, and infectious disease. She also guides the bioanalytical characterization of lead molecules through pharmacokinetic and Absorption, Distribution, Metabolism and Excretion (ADME) studies. In addition, Dr. Huang is responsible for the maintenance and growth of Venenum’s 5.7 million member compound collection for high-throughput screening.

Dr. Huang began her career with VENENUM Biodesign as a Chemistry Team Leader. In 2015 she was promoted to Assistant Director of Medicinal Chemistry a position she held until 2019 when she transitioned into the role of Director of Medicinal Chemistry.

Dr. Huang is a medicinal chemist with more than 20 years of experience in drug discovery which spans a variety of therapeutic areas including Metabolic Disease, Oncology, Respiratory, CNS, and Inflammatory Disease. She previously held positions with Pharmacopeia as a Research Scientist and Senior Group Leader as well as Ligand Pharmaceuticals as a Senior Research Investigator.

Dr. Huang received her BS in Chemistry from National Taiwan University in Taipei City, Taiwan. She earned a Ph.D. in Organic Chemistry at University of Texas at Austin in Austin, TX. Dr. Huang completed her post-doctoral fellowship in Organic Chemistry at Duke University in Durham, NC.

• 609-249-9578
• jhuang@gd3services.com
• 

Judit Kámán, Ph.D.

Managing Director

Dr. Kámán joined BioBlocks, Kft. in April 2008 as a project leader. Since this time she has been in charge of developing screening leads into a novel, patentable series, capable of producing a drug candidate in a one to three year time frame. She is currently supervising a team of 18 chemists, responsible for project management, customer relations and communication. During her employment at BioBlocks, she supervised two PhD students, who were working on palladium-catalyzed chemistry. Between 2005 and 2008, Dr. Kámán worked at Ubichem (Soneas), where she was the leader of a four-member group involved in the planning, development and production of organic compounds on scales up to 100's of grams. Previously, Dr. Kámán spent 4 years in a post-doctoral position at Laboratory for Organic and Bio-organic Synthesis, Department of Organic Chemistry, University of Gent, Belgium. Two of these years were supported by the Marie Curie Fellowship. She was awarded a Ph.D. in Organic Chemistry from University of Szeged. Dr. Kámán is a co-author of 10 publications.

• jkaman@gd3services.com
• 

William Solvibile,

Business Development Manager

Bill joined the team in 2015 as a Research Associate in the Chemistry Division at Venenum BioDesign. In 2021 he transitioned into the role of Business Development Manager for GD³.

Bill brought over 25 years experience in the Pharma and Contract Research industries working with small molecule to the team. He has extensive knowledge in analytical and spectral techniques including TLC, LC/MS, HPLC, flash chromatography, FTIR, 1H and 13C NMR. He is proficient in traditional and parallel synthesis and has experience in a number of diverse therapeutic areas including Cardiovascular/ Metabolic Disease, Women's Health and CNS disorders.

Bill’s previous experience in Pharma includes Wyeth Research, Pfizer and Provid Pharmaceuticals. Academia research experiences includes Rutgers University Waksman Institute.

Bill received a B.S. in Chemistry from Albright College in Reading, PA and a M.A. in Chemistry at Temple University in Philadelphia, PA. Bill is an inventor on four US patents.

• 609-865-2339
• wsolvibile@gd3services.com

Virág Bogdándi, Ph.D

Business Development Manager

As business development manager, Virág identifies and qualifies new prospects and business collaboration opportunities for the Chemistry Division by contacting decision makers at pharmaceutical and biotech companies operating in the drug discovery and preclinical development field. She collaborates with scientific management to convert opportunities into project proposals. She assists in decisions involving price structure and price negotiations, as well as the execution of contracts and service agreements. She establishes and maintains contact with clients to ensure high levels of client satisfaction.

Virág received a BSc in Chemistry and MSc in Organic Chemistry from the University of Debrecen, Faculty of Science and Technology in Debrecen, Hungary. She earned a Ph.D. in Interdisciplinary Medical Sciences at the University of Pécs, Faculty of Medicine in Pécs, Hungary.

Before joining GD³, Virág held positions at National Tumorbiology Laboratory as a Scientific Project Coordinator. She managed translational research projects and gained experience in scientific Business Development scouting and Sanofi and Euroapi.

Virag is a long-distance runner and competes between 5-21 km. She enjoys being active, cycling, and hiking in nature in the mountains. As a fan of gastronomy, she also spends a lot of her free time in the kitchen.

• 630-644-9913
• vbogdandi@gd3services.com
• 

Madeline Farley, Ph.D.

Chief Scientific Officer, Biochemistry & Bioanalytical Division

Dr. Farley is the Chief Scientific Officer, Biochemistry & Bioanalytical Division. Dr. Farley has 15 years of experience in neuroscience research and preclinical contract work, emphasizing molecular biology, biochemistry, biophysics and disease modeling. Dr. Farley joined PharmOptima in 2021 as a Senior Scientist within the Biochemistry group. Apart from her role in Biochemistry, she has worked closely with the Vivarium to establish ocular disease models within the Ocular Center of Excellence. Before joining PharmOptima, Dr. Farley investigated injury signaling pathways underlying neurodegenerative disease and neuronal injury using transgenic mice and AAV-based gene delivery systems targeting neurons within the retina. Dr. Farley received her BS in Biochemistry, with a minor in Mathematics, from Centenary College of Louisiana. She earned her Ph.D. in Cellular and Molecular Neuroscience at The University of Texas Health Science Center in Houston, TX. She completed postdoctoral fellowships at both McGovern Medical School at UTHealth and Baylor College of Medicine. Dr. Farley has been a recipient of a vision sciences postdoctoral fellowship through the National Eye Institute and an individual NRSA predoctoral fellowship through the National Institute of Neurological Disorders and Stroke.

• 269-492-3872
• mfarley@gd3services.com
• 

Phillip Zaworski

Director of Assay Development

Phil has over two decades of big pharma and biotech experience with deep biochemistry knowledge with a focus on immunoassays, protein expression, and molecular biology.

• 609 570 1081
• pgzaworski@gd3services.com
• 

James Beasley, Ph.D.

Managing Director, Venenum Biodesign Biology and IAS

Dr. Beasley joined the team in 2011. As Venenum’s Director of Biology, he oversees a team of scientists that support the research efforts in GBG’s pre-clinical drug discovery programs in therapeutic areas such as metabolic disorders, oncology, and infectious disease. Dr. Beasley’s Discovery Biology team specializes in the development, optimization, and execution of assays in the ultra-high-throughput screening (uHTS) of Venenum’s 5.7 million member compound library. The team also develops and performs assays, including several ADME-Tox assays, necessary to profile the small molecule therapeutic compounds produced by medicinal chemistry. Dr. Beasley serves as a member of the GBG Executive Council.

Dr. Beasley began his career with VENENUM Biodesign as the Discovery Biology Team Leader. In 2014 he was promoted to his current position as Director of Discovery Biology.

Dr. Beasley brought 12 years of experience in the Drug Discovery industry. He previously held positions with Ligand Pharmaceuticals as a Senior Research Investigator, Pharmacopeia as a Senior Principal Scientist, and DGI Biotechnology as a Senior Scientist.

Dr. Beasley received his BS in Chemistry from University of Texas at Austin in Austin, TX. He earned his PhD. in Chemistry at University of North Carolina at Chapel Hill in Chapel Hill, NC. Dr. Beasley completed his post-doctoral fellowship at Princeton University in Princeton, NJ.

• 609-249-9551
• jbeasley@gd3services.com
• 

Kelly Winchester

Chief Laboratory Strategy Officer

Kelly joined the team in 2004. As the Chief Laboratory Strategy Officer, Kelly is responsible for Kelly is responsible for overseeing and managing Medical Diagnostic Laboratories' clinical laboratory Customer Service, Quality Assurance, Quality Control, and the Clinical Laboratory.

Kelly began her career with MDL as a Laboratory Technician in 2004. In 2005 she became a Clinical Validation Technician and transitioned into the role of Clinical Implementation/Validation Coordinator in 2007. In 2010 Kelly was promoted to Assistant Director of the QA & QC Department. She held this position until 2012, when she became Director of Quality Control. In 2017 Kelly was promoted to Vice President of Clinical Laboratory Operations, a position she held until transitioning into her current role.

• 609-570-1000 ext. 1038
• kwinchester@gd3services.com

Deborah Giusto, MD

Pathologist and Managing Director

Dr. Giusto is board-certified in Anatomic and Clinical Pathology by the American Board of Pathology. She completed Pharmacy Curriculum at Lewis University in Romeoville, Illinois. She received both a Doctor of Pharmacy and Doctor of Medicine with honors from the University of Illinois in Chicago, Illinois. Dr. Giusto has published several abstracts and publications in peer-reviewed medical journals and contributed to a book chapter in a recently published authoritative textbook of liver pathology. Before earning her medical degree, Dr. Giusto was a pharmacist for ten years, working in an underserved area on the West Side of Chicago.

• dgiusto@gd3services.com

Martin E. Adelson, Ph.D.

Chief Operating Officer

Dr. Adelson joined the team in 2002. As the Chief Operating Officer, Dr. Adelson leads clinical, development, and discovery research operations in Medical Diagnostic Laboratories (MDL), Venenum Biodesign, and Invivotek with his main focus concentrating on scaling and expanding the existing business infrastructure through both organic growth and corporate acquisition. In addition, Dr. Adelson implements various innovations and re-engineering initiatives, as well as leverages customized technology solutions, to re-calibrate and enhance MDL's workflow while reducing overall business costs.

Prior to his appointment to Chief Operating Officer in 2013, Dr. Adelson held positions within MDL as Director of Research & Development before becoming Vice President of MDL in 2007.

Dr. Adelson received his BS in Biology from The College of New Jersey (formerly Trenton State College) in Ewing, NJ. He earned his Ph.D. in Molecular Biology & Genetics from the Department of Molecular Biology and Genetics/Fels Institute for Molecular Biology and Cancer at Temple University School of Medicine in Philadelphia, PA. He completed his postdoctoral studies in the Department of Microbiology and Molecular Genetics at the University of Medicine and Dentistry of New Jersey. Dr. Adleson was the proud recipient of a competitive Postdoctoral Research Fellowship from the National Institutes of Health, National Lung, and Blood Institute.

Dr. Adelson has presented more than 15 presentations for scientific meetings and conferences, clients, and special events. He is the author of 60 publications and 82 abstracts including:

• Adelson ME, Feola M, Trama JP, Tilton RC, and Mordechai E. (2005). Simultaneous detection of herpes simplex virus types 1 and 2 by real-time PCR and Pyrosequencing. Journal of Clinical Virology, 33(1): 15-34. ’s

Dr. Adelson is an Associate Professor at Rowan University Graduate School of Biomedical Sciences as well as a present Member of the Thomas Jefferson University Biotechnology Program Advisory Committee. He has served on the editorial boards of Diagnostic Microbiology and Infectious Disease and Journal of Clinical Microbiology. He has also served as a guest reviewer for the Journal of Clinical Microbiology, Infection & Immunity, Journal of Applied and Experimental Microbiology, Clinical and Diagnostic Microbiology, Journal of Dermatological Science, Diagnostic Microbiology and Infectious Disease, and Clinical and Vaccine Immunology. He serves as a Scientific Advisory Board member of JBS Science, Inc. at the PA Biotechnology Center and is a founding member of the New Jersey and Pennsylvania BioTech and Life Sciences Leadership Council. Dr. Adelson also holds a certificate as a Medical Director from the Wadsworth Center New York State Department of Health. His current professional memberships include the American Society of Microbiology, International Organization for Mycoplasmology, and Association for Molecular Pathology.

• 609-570-1015
• madelson@gd3services.com
• 

Jing-Jing Yang, MD

Pathologist

Dr. Yang is board-certified in Anatomic and Clinical Pathology and Cytopathology by the American Board of Pathology. She completed the Post-Baccalaureate Pre-Med curriculum at Rutgers College, Rutgers University in New Brunswick, New Jersey. She then went on to receive her M.D. from St. George’s University, in Grenada, West Indies. Dr. Yang completed her Anatomic and Clinical Pathology Residency at St. Lukes-Roosevelt, Beth Israel Medical Center in New York, NY, a Fellowship in Cytopathology at Mt. Sinai Medical Center in New York, NY, and a Fellowship in Genitourinary Pathology at Cleveland Clinic in Cleveland, Ohio.

• jyang@gd3services.com

Vladimir Khazak, Ph.D.

Head of Oncology

Dr. Vladimir Khazak is an experienced biologist with more than 20 years of working in multiple biopharmaceutical companies. He received an M.S. and Ph.D. from Chemical-Technical University, Moscow Institute for Genetics and Selection of Microorganisms, in Moscow, Russia. He completed his postdoctoral research at Fox Chase Cancer Center in Philadelphia, PA in the relationship between basic transcriptional apparatus and stress. Particular areas of expertise include genetics and molecular oncology with a particular emphasis on protein-protein interaction, gene regulation/expression and signal transduction.

• vladimir.khazak@gd3services.com

Graham Fletcher, Ph.D.

Chief Operating Officer, Disease Modeling Division

Dr. Fletcher joined the team in 2024. As Chief Operating Officer of the Disease Modeling Division of GD³, he provides leadership, oversight, and coordination for developing and managing operational components, including IACUC and GLP compliance activities and internal study scheduling. He works closely with clients and the Business Development team to understand their needs, design projects, and oversee their studies.

Dr. Fletcher is an accomplished preclinical and clinical drug development scientist and pharmacologist who has held senior roles in small molecule and therapeutic antibody programs. He brought to the team over 20 years of experience covering the drug development process from target discovery and validation through Phase I/II clinical trials with particular therapeutic expertise in Oncology and Immuno-oncology (IO). Dr. Fletcher has extensive experience in team and project management, leading multidisciplinary teams to take three oncology drugs from candidate selection through IND development into nine clinical trials. He deeply understands the drug development process and oncology and IO, encompassing biological, translational, and clinical science. He previously held positions with EntreMed Inc. as a Research Scientist III, Campbell Family Institute, within the University Health Network, Toronto and Treadwell Therapeutics as Head of Preclinical Development, and Medicenna Therapeutics as Director of Clinical Science.

Dr. Fletcher received a BSc in Molecular Biology at Edinburgh University in Edinburgh, Scotland. He earned a Ph.D. in Cell Biology from the University of Cambridge in Cambridge, United Kingdom. Dr. Fletcher is an author of over 20 publications and patents.

• 416-939-9590
• gfletcher@gd3services.com
• 

Emily S. Arcamone, B.S., RLATG

Business Development Account Manager, External Alliance Project Coordinator

Emily joined the team in 2013. As Business Development Account Manager and External Alliance Project Coordinator, she develops proposals and assist with the execution of contracts and service agreements. To accomplish that she works with scientific project leaders and project management staff to establish and initiate new study proposals. She interacts with cross-functional scientific directors through the strategic planning and delivery of the development program, proactively identifying and managing issues in order to ensure satisfactory turn-around-time to all incoming projects.



Emily has over 20 years of experience working in the biotechnology field, including over 15 years in a management role. She joined Invivotek’s management team as a Resource Coordination Manager from Taconic Biosciences, where she had a similar title. Emily has extensive experience in the planning, scheduling, and allocation of resources to maximize the efficiency of the team including in vivo and in vitro Research Associates
Emily received her B.S. in Animal Sciences from Rutgers University.

• 888-994-4870
• emarcamone@gd3services.com
• 

Fariba Chalajour, MD, MBA

Managing Director

Dr. Chalajour joined the team in 2020. As the Managing Director of Comparative Biosciences, Inc, a GLP preclinical CRO based in California, she manages the company’s operations, ensures high-quality preclinical studies, and provides strategic leadership in animal study design and to the histopathology team. By combining her business acumen with her 20 years of experience in experimental medicine and translational research, she fosters collaborative relationships with clients and stakeholders to successfully meet their project needs and regulatory requirements.

Prior to her current role, Dr. Chalajour held the position of VP of Preclinical Histopathology at Comparative Biosciences, Inc. In this role, she oversaw scientific and operational activities related to histopathology projects and formulated business objectives. She also managed the sales and marketing activities and developed client relationship management strategies. She was promoted to Managing Director in 2022.

Dr. Chalajour earned her medical degree from Azad University Medical School in Tehran, Iran. Her residency training was focused on cardiovascular surgery at University Heart and Vascular Center in Hamburg, Germany. Following this, she completed her research fellowship in cardiothoracic surgery at Stanford University Medical Center. Throughout her career, Dr. Chalajour has contributed to scientific literature and presented her research findings at conferences. She has been involved in multiple peer-reviewed articles and worked as a consultant to various pharmaceutical and medical device companies.

Kelsey E. Huntington, Ph.D.

Business Development Manager

Dr. Huntington joined the team in 2023. As a Client Relationship Manager at Comparative Biosciences, Inc., a preclinical CRO based in California, she promotes the company's portfolio of preclinical toxicology services to secure new accounts and to grow existing accounts with clients in pharmaceutical, biotech, and academic sectors. Dr. Huntington provides consultative scientific solutions to clients by identifying and addressing their unmet needs using the custom services offered at Comparative Biosciences, Inc. to create collaborative long-term relationships.

Dr. Huntington received her B.Sc. in Molecular, Cellular, and Developmental Biology from the University of Washington in Seattle, WA. She earned her Ph.D. in Pathobiology from Brown University in Providence, RI. Dr. Huntington was awarded an NIH Ruth L. Kirschstein National Research Service Award (F31) grant by the National Institutes of Health and the National Cancer Institute to support her predoctoral research in cancer immunology at Brown University. She was also the proud recipient of several awards from the American Association for Cancer Research including the Women in Cancer Research Scholarship Award, the AACR-WuXi AppTec Scholar-in-Training Award, and the AACR AbbVie Scholar-in-Training Award. Dr. Huntington was also named a Frederic Poole Gorham Pre-Doctoral Fellow by Brown University.

Dr. Huntington has given more than 15 presentations at scientific meetings and conferences. She is the author of over 25 peer-reviewed scientific publications, 1 textbook chapter, 5 patents and patent applications, and 40 abstracts.

Dr. Huntington is a Board Member of the Women in STEM (WiSTEM) Organization and was formerly a member of the National Advisory Council. She is an Associate Faculty Member of Faculty Opinions and has served as a guest reviewer for eLife and Translational Research. Her current professional memberships include the Association for Women In Science, the American Association for Cancer Research, the Society for Immunotherapy of Cancer, and the American Society for Investigative Pathology.

• 475-326-1044
• khuntington@gd3services.com
• 

John Sampalis, B.Sc., B.A.(Hon), M.Sc., Ph.D., F.A.C.E, F.A.H.A

Chief Scientific Officer

Dr. Sampalis joined the team in 2023. As CEO and Chief Scientific Officer of JSS Medical Research. He is a tenured professor of Surgery and Epidemiology & Biostatistics of McGill University, the University of Montreal and Laval University. Throughout his career he has received numerous scholarships from provincial and federal funding agencies including the Medical Research Council of Canada, the National Health Development Program and the Fonds de la recherche en santé du Quebec. With over 175 peer-reviewed publications in high ranking journals and more than seven million dollars in research funding, Dr. Sampalis is recognized as one of the leading clinical epidemiologists in the world, and one of the top trauma researchers in Canada.

Possessing extensive expertise in health services research, clinical trials and the evaluation of medical technology, Dr. Sampalis also offers services as a Research and Epidemiological Consultant for numerous pharmaceutical companies, hospitals and government organizations and agencies.

Dr. Sampalis currently holds a Medical Scientist Salary Award from the Medical Research Council of Canada and has previously received numerous prestigious scholarships and awards including the National Health Research and Development Scholar from Health Canada. In addition, he participates as a reviewer for over five leading peer-reviewed journals and as a committee member for provincial and federal funding agencies.

As Chief Scientific Officer at JSS Medical Research, he continues to contribute to scientific aspects of the clinical trials in collaboration with the VP, Scientific Affairs team to ensure sound scientific expertise and that data quality and integrity are maintained.

• +1 514 934-6116
• jsampalis@gd3services.com
• 

Emmanouil Rampakakis, Ph.D.

Chief Business Officer

Dr. Rampakakis joined the team in 2023 following the acquisition of JSS Medical Research. As the Chief Business Officer of the Clinical Division, he is responsible for strategy development, oversees business development, manages partnerships, and contributes to workflow optimization focusing on growth and profitability.

He has over 20 years of experience in medical and clinical research, has contributed to the conception, design, analysis and interpretation of more than 150 large scale, national and international, registration and real-world studies, and has contributed to 8 market approvals.

He is an adjunct member of the department of pediatrics of McGill University, collaborator in multiple academic grants in the field of pediatrics, and an author on over 100 peer-reviewed publications and over 300 presentations at international conferences. In addition, he serves as a reviewer for over five peer-reviewed journals, grant reviewer, and advisor for pharmaceutical, biotechnology, medical device, cannabis, and psychedelics companies.

Dr. Rampakakis received his Ph.D. from the Department of Biochemistry in McGill University and the McGill Cancer Centre and obtained post-doctoral training in Pharmacoepidemiology at McGill University and the Jewish General Hospital.

• 514 934-6116 ext. 249
• ERampakakis@gd3services.com
• 

Peter Heessels,

Director of Business Development

Mr. Heessels holds a Bachelor's degree in Biochemistry from McGill University as well as a Masters of Business Administration from the John Molson School of Business at Concordia University. He has over 25 years of experience in Business Development in the CRO industry. He has excellent knowledge of the drug development process, from preclinical to Phase IV, with a strong regulatory and clinical background including bioanalytics and manufacturing. Mr. Heessels has demonstrated his ability to help companies identify gaps in their product’s development path and chart the quickest path to proof of concept and/or regulatory approval. Obtaining win-win solutions has allowed Mr. Heessels to build and maintain large, long-term profitable business and client relationships and is interested in supporting biotechnology, pharmaceutical and medical device companies looking to create a positive impact in their respective therapeutic areas.

• 514 934-6116 ext. 114
• pheessels@gd3services.com
•